Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Zanubrutinib Tablet vs Capsules
NCT05767398Phase 1Completed
- Sponsor
- BeiGene
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM) and 3 more (2 arms), sponsored by BeiGene. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and 6 more. Started Mar 2023; status: completed.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05767398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767398.